| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Nanjing Well Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥24.68 |
| 52 Week High | CN¥29.80 |
| 52 Week Low | CN¥17.65 |
| Beta | 0.38 |
| 1 Month Change | 9.74% |
| 3 Month Change | 14.26% |
| 1 Year Change | -0.64% |
| 3 Year Change | 17.30% |
| 5 Year Change | -5.65% |
| Change since IPO | -5.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603351 | CN Chemicals | CN Market | |
|---|---|---|---|
| 7D | 3.7% | 4.3% | 4.4% |
| 1Y | -0.6% | -17.4% | -12.6% |
Return vs Industry: 603351 exceeded the CN Chemicals industry which returned -17.4% over the past year.
Return vs Market: 603351 exceeded the CN Market which returned -12.6% over the past year.
Price Volatility
| 603351 volatility | |
|---|---|
| 603351 Average Weekly Movement | 5.4% |
| Chemicals Industry Average Movement | 8.7% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 603351 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603351's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 658 | Renrong Wu | www.well-js.com |
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical auxiliary materials in China. Its pharmaceutical materials include excipients for injectables and non-injectables.
Nanjing Well Pharmaceutical Group Co.,Ltd. Fundamentals Summary
| 603351 fundamental statistics | |
|---|---|
| Market cap | CN¥3.26b |
| Earnings (TTM) | CN¥94.75m |
| Revenue (TTM) | CN¥1.09b |
35.3x
P/E Ratio3.1x
P/S RatioIs 603351 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603351 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.09b |
| Cost of Revenue | CN¥813.67m |
| Gross Profit | CN¥275.04m |
| Other Expenses | CN¥180.30m |
| Earnings | CN¥94.75m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.70 |
| Gross Margin | 25.26% |
| Net Profit Margin | 8.70% |
| Debt/Equity Ratio | 33.7% |
How did 603351 perform over the long term?
See historical performance and comparison